Company news

Vaxcyte, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

October 9, 2026

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

October 6, 2026

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

October 5, 2026

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

October 5, 2026

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

October 5, 2026

Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

October 4, 2026

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

September 3, 2026

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

August 5, 2026

Vaxcyte to Participate in Upcoming Investor Conferences

July 8, 2026

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

June 2, 2026

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

April 6, 2026

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

March 22, 2026

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

March 17, 2026

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 24, 2026

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

February 11, 2026

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

February 10, 2026

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

February 5, 2026

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 2, 2026

Vaxcyte Announces Pricing of $550 Million Public Offering

January 29, 2026

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

January 29, 2026

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

January 21, 2026

Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

December 7, 2025

Medicxi Announces €500 Million Fund V

November 14, 2025

Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

November 3, 2025

Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services

September 29, 2025

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

September 2, 2025

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)

August 5, 2025

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

April 30, 2025

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

March 30, 2025

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

March 29, 2025

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 24, 2025

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

February 11, 2025

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

February 4, 2025

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

January 29, 2025

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

December 2, 2024

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

November 11, 2024

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

November 4, 2024

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

September 10, 2024

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 5, 2024

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

September 3, 2024

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

September 2, 2024

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

September 1, 2024

Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

August 5, 2024

Vaxcyte Appoints John Furey to Board of Directors

July 1, 2024

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

March 3, 2024

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 26, 2024

Older news releases →

Calls

Decks

The 5 newest of 9 decks. Every deck is listed under its year.